Evidence map›Paper›PMID 41924336›Full record

ArticleCHEST pulmonary2026

Increased Xanthine Oxidoreductase Activity in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

Julie C Coursen, Tijana Tuhy, Adrianne Woods, Laura K Hummers, Ami A Shah, Paul M Hassoun, Rachel L Damico, Stephen C Mathai, Catherine E Simpson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julie C CoursenDivisions of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.
Tijana TuhyDivisions of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.
Adrianne WoodsRheumatology, Johns Hopkins University, Baltimore, MD.
Laura K HummersRheumatology, Johns Hopkins University, Baltimore, MD.
Ami A ShahRheumatology, Johns Hopkins University, Baltimore, MD.
Paul M HassounDivisions of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.
Rachel L DamicoDivision of Pulmonary, Critical Care, and Sleep Medicine, University of Miami, Miami, FL.
Stephen C MathaiDivisions of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.
Catherine E SimpsonDivisions of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD.

Funding

MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007534 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Nadia N Hansel, Larissa A. Shimoda · 1985 to 2026
$28.3M
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in sclerodermaK24AR080217 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Ami Aalok Shah · 2022 to 2026
$847k
NHLBI NIH HHS T32 HL007534NIAMS NIH HHS K24 AR080217
6 · The paper itself

Abstract

backgroundPreclinical studies have demonstrated the importance of xanthine oxidoreductase (XOR) in the pathobiology of pulmonary hypertension (PH) through generation of uric acid, reactive oxygen species, and vascular endothelial dysfunction. RESEARCH QUESTION: In 2 well-characterized cohorts of patients with systemic sclerosis (SSc), what is the relationship of systemic XOR enzymatic activity to PH diagnosis, development, and severity? STUDY DESIGN AND

methodsSerum samples from 48 patients with systemic sclerosis-associated pulmonary hypertension (SSc-PH) were assayed for XOR activity using an enzyme-linked immunosorbent assay (ELISA) in a discovery cohort from the Johns Hopkins Pulmonary Hypertension Program, including 12 index treatment-naive patients with samples collected before and after 36 weeks of PH-specific therapy. Sixty-nine patients with SSc-PH were compared with patients with SSc without PH in a second cohort from the Johns Hopkins Scleroderma Center using a nested case-control design. Patients in the Johns Hopkins Scleroderma Center cohort were under longitudinal surveillance for development of right heart catheterization-confirmed PH, which allowed for serum collection at proximate and distant time points before PH diagnosis (1 proximate sample within 12 months of PH diagnosis and 1 distant sample within 5 years of PH diagnosis, with a minimum 6-month separation between samples).

resultsXOR activity temporally correlated with SSc with pulmonary arterial hypertension disease development, and increasing XOR activity over the time preceding PH diagnosis was associated with worse disease severity by invasive hemodynamics. In a small subset of patients, XOR activity increased after initiation of PH-specific therapy.

interpretationTaken together, these results suggest increased XOR activity and hyperuricemia may represent modifiable risk factors in SSc-PH.

Indexed as

pulmonary arterial hypertensionscleroderma

Identifiers

PMID41924336
PMCPMC13038047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.